BRAFV600 wild-type status tied to poorer survival in advanced melanoma
Survival is worse among patients with advanced BRAFV600 wild-type melanoma than those with BRAFV600-mutant advanced melanoma during the first 10 months following diagnosis due to limited treatment options, according to a Dutch study.
BRAFV600 wild-type status tied to poorer survival in advanced melanoma
28 Feb 2021
